Actualités sur Health

13.09.2016 – 12:01
Novo Nordisk
Adults with Type 2 Diabetes Treated with Xultophy® (IDegLira) were up to 4.5 Times More Likely to Reach Glycaemic Targets Without Hypoglycaemia and Weight Gain vs Up-titration with Insulin Glargine U100
Munich, Germany (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today presented data showing the odds of reaching fasting plasma glucose (FPG) targets without hypoglycaemia and weight gain were significantly ...
plus
13.09.2016 – 12:01
Novo Nordisk
Semaglutide Demonstrated Superior HbA1c Reduction vs Placebo as Add-on to Basal Insulin Alone or with Metformin in Adults with type 2 Diabetes
Munich (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk today announced that semaglutide, an investigational glucagon-like peptide-1 (GLP-1) analogue administered once-weekly, significantly improved glycaemic ...
plus
12.09.2016 – 15:09
Merck Healthcare Germany
Merck Presents New Data on the Safety and Durable Efficacy of Cladribine Tablets and Advantages of Early Treatment with Rebif® at the 2016 ECTRIMS Congress
Darmstadt, Germany (ots/PRNewswire) - - Two oral presentations and nine posters include new analyses on investigational Cladribine Tablets - Real-world data assess the safety, tolerability and effectiveness of Rebif® - Symposium highlights unmet needs among patients with MS and real-word issues - Grant for Multiple ...
plus
07.09.2016 – 08:04
CROMSOURCE
CROMSOURCE Appoints Chief Medical Officer and Expands Medical Affairs Services
Verona, Italy (ots/PRNewswire) - CROMSOURCE, an international contract research organization (CRO) providing a comprehensive portfolio of services to the pharmaceutical, biotechnology, and medical device industries, announced today the appointment of its new Chief Medical Officer, Dr. Grzegorz Rychlik, and the expansion of its Medical Affairs Services department. ...
plus
05.09.2016 – 10:01
Royal Philips
Philips Showcases Portfolio of Connected Sleep and Respiratory Solutions at the European Respiratory Society International Congress 2016
Amsterdam and London (ots/PRNewswire) - Philips to highlight the Dream Family connected therapy system, announcing its extension with the introduction of BiPAP autoSV and BiPAP AVAPS therapy devices Philips Respironics (http://www.respironics.com/), a division of Royal Philips (http://www.usa.philips.com/) (NYSE: ...
plus
30.08.2016 – 09:02
Daiichi Sankyo Europe GmbH
ENSURE-AF Data Support the Efficacy and Safety Profile of Daiichi Sankyo's Once-Daily LIXIANA® (edoxaban) in Patients with Atrial Fibrillation Undergoing Cardioversion
Munich (ots/PRNewswire) - Not for US or UK media - ENSURE-AF is the largest clinical trial of a non-vitamin K antagonist oral anticoagulant in patients with non-valvular atrial fibrillation - who undergo electrical cardioversion - ENSURE-AF is a Prospective, Randomized, Open-Label, Blinded E ndpoint evaluation ...
plus

29.08.2016 – 17:58
Resverlogix Corp.
Resverlogix Hosts Symposium to Discuss the Role of BET-inhibition in Modifying Cardiovascular Risk at the ESC Congress in Rome, Italy
Calgary, Alberta (ots/PRNewswire) - The presentations at the ESC Congress symposium highlighted apabetalone and the opportunity and need for a novel approach to the treatment of high risk cardiovascular disease and diabetes. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that on Sunday, ...
plus
29.08.2016 – 16:49
Shire Pharmaceuticals Group Plc
Shire's First Prescription Eye Drop, Xiidra(TM) (lifitegrast ophthalmic solution) 5% is Now Available in the U.S.
Lexington, Massachusetts (ots/PRNewswire) - - Xiidra is the only prescription eye drop approved by the U.S. FDA for the treatment of both signs and symptoms of dry eye disease - Resources are available to support patients seeking information regarding coverage and savings offers - Xiidra is the first medication in a ...
plus
29.08.2016 – 08:31
Daiichi Sankyo Europe GmbH
Real World Data From PREFER in AF Patient Registry Highlights Increased Stroke Risk Among Diabetes Patients in Atrial Fibrillation
Munich (ots/PRNewswire) - Sub-analysis data from atrial fibrillation patient registry sponsored by Daiichi Sankyo reveals at-risk patient groups and recent trends in disease management[1],[2] Not for US media Daiichi Sankyo Europe GmbH (hereafter, Daiichi Sankyo) today announced data from new sub-analyses of the ...
plus
25.08.2016 – 13:03
Shire Pharmaceuticals Group Plc
Shire and Jennifer Aniston Want to Inspire People to Show Their Eyes Some Love and Help Raise Awareness of Chronic Dry Eye
Lexington, Massachusetts (ots/PRNewswire) - Jennifer Aniston Opens Up about Personal Experience with Dry Eye Symptoms, Which Have Been Reported by Nearly 30 Million Americans Jennifer Aniston is one of the millions of Americans who experience symptoms consistent with Chronic Dry Eye. Commonly referred to as Dry Eye, ...
plus
24.08.2016 – 09:01
Daiichi Sankyo Europe GmbH
Data from Phase 3b ENSURE-AF Study Investigating Once-Daily LIXIANA® (edoxaban)in Patients with Atrial Fibrillation Undergoing Cardioversion Among 13 Daiichi Sankyo Clinical Presentations at ESC Congress 2016
Munich (ots/PRNewswire) - - ENSURE-AF results to be featured during a late-breaking clinical trial session - Five abstracts highlighting analyses from the global phase 3 ENGAGE AF-TIMI 48 study to be presented - Seven abstracts to reveal new findings from the PREFER in AF and VTE European patient registries Daiichi ...
plus
16.08.2016 – 15:27
Nordion (Canada) Inc.
Sterigenics International and its Subsidiary Nordion Enter into Agreement to Acquire REVISS Services
Kanata, Ontario (ots/PRNewswire) - Agreement Highlights - Purchase agreement covers REVISS Services (UK) Ltd. and subsidiary REVISS Services Inc. (USA) - REVISS had ceased trading in cobalt-60 in April 2014 - REVISS Services will be integrated into the operations of Nordion (Canada) Inc. - Acquisition allows Nordion ...
plus

16.08.2016 – 14:58
ViiV Healthcare
ViiV Healthcare Launches Phase III Programme Evaluating a Two-drug Regimen Combining Dolutegravir and Lamivudine for HIV-1 Treatment
London (ots/PRNewswire) - ViiV Healthcare today announced the start of a phase III programme to support regulatory filings for a two-drug regimen of dolutegravir (Tivicay®) and lamivudine (Epivir®) as a treatment for HIV-1 infection in adults who have not received prior antiretroviral therapy. (Logo: ...
plus
15.08.2016 – 16:02
Oncopeptides AB
Oncopeptides Welcomes New Board Member - Luigi Costa
Stockholm (ots/PRNewswire) - Mr Costa, currently CEO of Nordic Nanovector ASA, a biotech company focused on the development of innovative treatments in hematology and oncology, brings to Oncopeptides more than 20 years' experience in the international pharmaceutical and biotech industry. Prior to his current position, he was Vice President of Europe, Middle East and Africa for Onyx Pharmaceuticals Inc. where he led the ...
plus
11.08.2016 – 13:01
Resverlogix Corp.
Resverlogix Announces Positive Recommendation From Data Safety Monitoring Board for Phase 3 Study of Apabetalone (RVX-208)
Calgary, Alberta (ots/PRNewswire) - A data review by the independent Data Safety Monitoring Board resulted in a verbal recommendation for the BETonMACE trial to continue as planned without any modification. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that the independent Data and ...
plus
09.08.2016 – 12:31
Accuray Europe
Accuray CE Marks Its New Radixact(TM) System
Sunnyvale, California (ots/PRNewswire) - Next Generation Image-Guided Radiation Therapy Platform and Integrated Software Solutions are Now Available for Use by Clinicians in the European Union Accuray Incorporated (NASDAQ: ARAY) announced today that it has CE marked its Radixact(TM) Treatment Delivery System, Accuray Precision(TM) Treatment Planning System and iDMS(TM) Data Management System. The next generation hardware ...
plus
28.07.2016 – 08:27
Merck Healthcare Germany
Merck and AmoyDx Collaborate to Bring Liquid Biopsy RAS Biomarker Testing to China
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - Liquid biopsy RAS biomarker test based upon AmoyDx's real-time PCR technology, ADx-SuperARMS®, will be made available in China in 2017 - Merck is the first pharmaceutical company to collaborate with multiple diagnostic providers to support liquid biopsy RAS biomarker testing worldwide ...
plus
27.07.2016 – 14:01
TauRx Therapeutics
TauRx Reports First Phase 3 Results for LMTX®
Aberdeen, Scotland and Singapore (ots/PRNewswire) - Promising Read-Out for First-Ever Tau Aggregation Inhibitor to Enter Phase 3 Trials - LMTX® as monotherapy demonstrates significant reductions in disease progression in mild and moderate Alzheimer's disease - Strong results in both cognitive and functional tests supported by brain scan evidence of slow-down in progression of pathology - Study misses co-primary endpoints ...
plus

25.07.2016 – 08:01
Shire Pharmaceuticals Group Plc
ONIVYDE® Receives Positive CHMP Opinion for Treatment of Patients with Metastatic Adenocarcinoma of the Pancreas Who Have Progressed Following Gemcitabine Based Therapy
Zug, Switzerland (ots/PRNewswire) - The positive opinion is based on a pivotal Phase 3 study showing that ONIVYDE combined with chemotherapy significantly increased overall survival (OS) in patients with metastatic pancreatic cancer after previous gemcitabine based therapy Shire plc (LSE: SHP, NASDAQ: SHPG) today ...
plus
21.07.2016 – 21:29
Resverlogix Corp.
Resverlogix Announces Dosing of First Two Patients in Expanded Renal and Orphan Programs
Calgary, Alberta (ots/PRNewswire) - The commencement of this Phase 1 pharmacokinentic (PK) trial in patients with severe renal impairment is the first in a series of planned clinical trials designed with value creation in mind. Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) today announced that dosing has commenced in a Phase 1 PK study with lead drug ...
plus
21.07.2016 – 19:33
Accuray Europe
TomoTherapy® System Provides Favorable Cosmetic Outcomes Without Compromising Efficacy in Low-Risk Breast Cancer Patients
Sunnyvale, California (ots/PRNewswire) - Accuray Incorporated (NASDAQ: ARAY) announced today preliminary results from a prospective, phase II trial evaluating once-daily accelerated partial breast irradiation (APBI) in patients treated with the TomoTherapy® System. The study, published in the June issue of the ...
plus
21.07.2016 – 13:01
Shire Pharmaceuticals Group Plc
Shire Launches Pediatric Indication for Immunodeficiency Treatment HyQvia in Europe
Zug, Switzerland (ots/PRNewswire) - HyQvia (Human Normal Immunoglobulin 10% and Recombinant Human Hyaluronidase) is the only subcutaneous IG treatment for primary and certain secondary immunodeficiencies that can be administered in one site, once a month (up to every four weeks) Shire plc (LSE: SHP, NASDAQ: SHPG) is launching a pediatric indication for HyQvia (Human ...
plus
18.07.2016 – 12:16
ViiV Healthcare
ARIA Study Shows Superior Efficacy of Triumeq® for Treatment-naïve Women Living with HIV
London, England and Durban, South Africa (ots/PRNewswire) - ViiV Healthcare today presented 48-week data from the phase IIIb, open-label, international, multi-centre ARIA study which showed superior efficacy for Triumeq® (dolutegravir/abacavir/lamivudine) compared with atazanavir boosted with ritonavir (ATV/r) plus tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) ...
plus
18.07.2016 – 08:01
Merck Healthcare Germany
Merck Receives European Medicines Agency Acceptance for Review of Marketing Authorization Application for Cladribine Tablets
Darmstadt, Germany (ots/PRNewswire) - Merck, a leading science and technology company, today announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of the investigational product Cladribine Tablets for the treatment of relapsing-remitting multiple ...
plus

13.07.2016 – 08:01
Takeda Pharmaceutical Company Limited
IBD Unmasked, a First-of-its-Kind Global Awareness Initiative, Launches to Support and Empower the Inflammatory Bowel Disease Community
Osaka, Japan (ots/PRNewswire) - Takeda unveils new IBD Super Hero and graphic illustrations, developed in collaboration with Marvel Custom Solutions, to highlight the strength of and inspire confidence in those living with IBD If someone with inflammatory bowel disease (IBD) was a Super Hero, what would that hero ...
plus
12.07.2016 – 01:10
Shire Pharmaceuticals Group Plc
Regulatory Approval - FDA Approves Shire's Xiidra(TM) (lifitegrast ophthalmic solution) 5% - The Only Treatment Indicated for the Signs and Symptoms of Dry Eye Disease
Lexington, Massachusetts (ots/PRNewswire) - - An estimated 16 million people in the U.S. are diagnosed with dry eye disease - Xiidra is the first prescription eye drop FDA-approved to treat both the signs and symptoms of dry eye disease - U.S. launch of Xiidra planned for third quarter 2016 Shire plc (LSE: SHP, ...
plus
11.07.2016 – 18:01
Novo Nordisk
Novo Nordisk to Present 28 Abstracts at the World Federation of Hemophilia Congress
Bagsværd, Denmark (ots/PRNewswire) - This material is intended for global medical media only. For journalistic assessment and preparation before publication. Novo Nordisk announced today that data from 28 abstracts will be shared at the upcoming World Federation of Hemophilia World Congress (WFH) in Orlando, Florida, from 24-28 July. The WFH Congress is the largest ...
plus
07.07.2016 – 08:01
Shire Pharmaceuticals Group Plc
Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
Zug, Switzerland (ots/PRNewswire) - This press release is intended for a global audience. First therapy indicated in the EU for use in patients aged one year and above with SBS, a rare gastrointestinal condition Shire (LSE: SHP, NASDAQ: SHPG) today announced that the European Commission has granted extension of ...
plus
01.07.2016 – 10:43
Merck Healthcare Germany
Results of Pivotal TAILOR Study Confirm Addition of Erbitux to FOLFOX Significantly Improves Outcomes in RAS Wild-Type Metastatic Colorectal Cancer
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media WCGC Abstract # 0-025; poster presentation, July 1, 2016, 10:35 am CEST - Phase III study shows response rate of 61.1% for patients treated with Erbitux plus FOLFOX - 31% decrease in risk of disease progression and 24% decrease in risk of ...
plus
01.07.2016 – 08:19
LEO Pharma
LEO Pharma Enters Biologics Through Strategic Partnership With AstraZeneca
Ballerup, Denmark (ots/PRNewswire) - LEO Pharma is a significant step closer to realising its vision of becoming the preferred dermatology care partner following a strategic partnership with AstraZeneca announced today. (Logo: http://photos.prnewswire.com/prnh/20130221/595427 ) The partnership covers potential new medicines for atopic dermatitis and psoriasis, two of ...
plus

Précédent33343536373839404142Suivant